Patients with a rare form for amyloidosis with polyneuropathy could soon have access to a new subsidised therapy, with the Pharmaceutical Benefits Advisory Committee supporting a PBS listing for patisiran.
The drug is a novel small interfering RNA therapy that attaches to mRNA to inhibit the mutant TTR gene that produces the transthyretin protein causing TTR-related amyloidosis.
Per the recommendation, the treatment would be available for the treatment of patients with (hereditary transthyretin-mediated) hATTR amyloidosis with polyneuropathy, (also referred to as variant ATTR amyloidosis, ATTRv).
Estimated to number about 50,000 worldwide, this population is understood to be about one-fifth the size of those with wild-type (wtATTR), and have a “high clinical need for effective treatment”, the PBAC said.
However, patisiran had shown clinical benefits in terms of delaying disease progression, reducing neuropathy symptoms, and improving health-related quality of life compared to placebo, based on the primary and secondary outcomes in the APOLLO trial over its 18-month trial period, the committee said (link here).
Branded Onpattro (Alnylam), patisiran is formulated as an IV infusion to be given every three weeks in addition to best supportive care.